You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Unresectable locally advanced esophageal squamous carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemo)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Split-course hypo-CCRT
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Aug 26, 2023

Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (LBL-007,

Not yet recruiting
  • Esophageal Cancer
  • +2 more
  • (no location specified)
Aug 21, 2023

Locally Advanced Unresectable Esophageal Squamous Carcinoma Trial in Jinan, Tianjin (Docetaxel for Injection (Albumin-bound),

Not yet recruiting
  • Locally Advanced Unresectable Esophageal Squamous Carcinoma
  • Docetaxel for Injection (Albumin-bound)
  • +4 more
  • Jinan, Shandong, China
  • +1 more
Nov 16, 2023

Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Toripalimab, Paclitaxel-albumin, Nedaplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Oct 25, 2022

Esophageal Squamous Cell Carcinoma Trial (AK104)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Oct 25, 2022

Esophageal Squamous Cell Carcinoma Trial (QL1706)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Aug 4, 2022

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai (CS1001+

Active, not recruiting
  • Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
  • CS1001+ Fluorouracil+Cisplatin
  • Placebo+ Fluorouracil+Cisplatin
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Mar 20, 2022

Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Cisplatin+Capecitabine+Sintilimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Zhengzhou, China
    The First Affiliated Hospital of Zhengzhou University
Aug 19, 2021

Chemo, Radiation Therapy Trial in Fuzhou (Camrelizumab, Paclitaxel, Cisplatin)

Not yet recruiting
  • Chemotherapy
  • Radiation Therapy
  • Fuzhou, China
    Fujian Medical University Union Hospital
Apr 6, 2023

Esophagus Cancer Trial in Guangzhou (Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy)

Not yet recruiting
  • Esophagus Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Nov 20, 2023

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC Trial in Hanzhou (Cadonilimab Combined Albumin-paclitaxel,

Recruiting
  • The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
  • Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
  • Hanzhou, Zhejiang, China
    Lulu Liu
Jul 14, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +129 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Apr 8, 2022

ESCC or Esophageal Adenosquamous Carcinoma Trial in Guangzhou (HLX07+HLX10+ Cisplatin+5-FU, HLX07)

Recruiting
  • ESCC or Esophageal Adenosquamous Carcinoma
  • HLX07+HLX10+ Cisplatin+5-FU
  • HLX07
  • Beijing, Beijing, China
  • +16 more
Aug 25, 2022

Esophageal Carcinoma Trial (Immune Checkpoint Inhibitors)

Not yet recruiting
  • Esophageal Carcinoma
  • Immune Checkpoint Inhibitors
  • (no location specified)
Jul 6, 2023

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 30, 2023

Esophageal Squamous Cell Carcinoma Trial in China (Sitravatinib, Tislelizumab, Docetaxel)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Hefei, Anhui, China
  • +29 more
Jul 28, 2022

Immunotherapy Esophagus Cancer Trial (Tislelizumab, Albumin paclitaxel, Nedaplatin)

Not yet recruiting
  • Immunotherapy Esophagus Cancer
  • (no location specified)
Aug 24, 2022

Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Cadonilimab combined Anlotinib
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023

Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • AK104, nab-paclitaxel, carboplatin
  • Anyang, Henan, China
  • +1 more
Jun 1, 2023

Esophageal Squamous Cell Carcinoma Trial (XH-30002 capsule, Afatiinb tablet)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • XH-30002 capsule
  • Afatiinb tablet
  • (no location specified)
Jun 25, 2023

Squamous Cell Carcinoma Trial (MK-3475A)

Not yet recruiting
  • Squamous Cell Carcinoma
  • MK-3475A
  • (no location specified)
Sep 11, 2023

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Chemoimmunotherapy
  • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
  • (no location specified)
Feb 14, 2023

Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial (cadonilimab+chemo)

Not yet recruiting
  • Resectable Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • (no location specified)
Apr 18, 2023

Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Unresectable Trial in Tianjin (tislelizumab+ Paclitaxel + Cisplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
  • Unresectable
  • tislelizumab+ Paclitaxel + Cisplatin
  • Tianjin, Tianjin, China
    Hongjing Jiang
Jul 7, 2022

Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy Trial (chemo combined with PD-1 inhibitors)

Not yet recruiting
  • Esophageal Squamous Cell Carcinomas
  • +3 more
  • chemotherapy combined with PD-1 inhibitors
  • (no location specified)
Nov 17, 2022